AngioDynamics (NASDAQ:ANGO) Earns “Buy” Rating from Canaccord Genuity Group

Posted by Brenda Bartman on Oct 9th, 2026

AngioDynamics (NASDAQ:ANGO – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at Canaccord Genuity Group in a research note issued on Friday, Benzinga reports. They presently have a $20.00 price target on the medical instruments supplier’s stock. Canaccord Genuity Group’s price objective would suggest a potential upside of 75.99% from the stock’s current price.

A number of other analysts have also weighed in on ANGO. HC Wainwright raised their target price on AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Wall Street Zen raised shares of AngioDynamics from a “hold” rating to a “buy” rating in a research report on Saturday, August 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. Finally, Zacks Research upgraded AngioDynamics from a “strong sell” rating to a “hold” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $19.50.

Read Our Latest Analysis on AngioDynamics

AngioDynamics Stock Up 1.2%

Shares of AngioDynamics stock traded up $0.13 on Friday, hitting $11.36. 574,440 shares of the company traded hands, compared to its average volume of 497,951. The company has a 50-day moving average price of $15.39 and a 200 day moving average price of $13.11. AngioDynamics has a 12-month low of $9.39 and a 12-month high of $16.29. The company has a market cap of $477.86 million, a PE ratio of -13.03 and a beta of 0.30.

AngioDynamics (NASDAQ:ANGO – Get Free Report) last issued its quarterly earnings data on Thursday, October 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.The business had revenue of $80.92 million for the quarter, compared to the consensus estimate of $80.51 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Equities research analysts anticipate that AngioDynamics will post -0.25 EPS for the current year.

Insiders Place Their Bets

In other AngioDynamics news, SVP Warren Jr sold 23,370 shares of the business’s stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total transaction of $344,006.40. Following the sale, the senior vice president owned 64,745 shares of the company’s stock, valued at approximately $953,046.40. The trade was a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 6.00% of the stock is owned by corporate insiders.

Institutional Trading of AngioDynamics

A number of institutional investors have recently bought and sold shares of the company. Integrated Wealth Concepts LLC bought a new stake in AngioDynamics in the second quarter worth approximately $38,000. Corient Private Wealth LP acquired a new position in shares of AngioDynamics during the second quarter valued at about $134,000. Public Employees Retirement System of Ohio bought a new position in shares of AngioDynamics during the 2nd quarter worth about $64,000. Bank of America Corp DE acquired a new stake in shares of AngioDynamics in the 2nd quarter valued at about $4,490,000. Finally, Gallagher Fiduciary Advisors LLC acquired a new stake in shares of AngioDynamics in the 2nd quarter valued at about $589,000. Institutional investors own 89.43% of the company’s stock.

Key Headlines Impacting AngioDynamics

Here are the key news stories impacting AngioDynamics this week:

Positive Sentiment: Quarterly results beat adjusted earnings expectations. AngioDynamics reported an adjusted loss of $0.04 per share, better than the consensus loss estimate of $0.11, while revenue reached approximately $80.9 million. GAAP net loss narrowed year over year, and gross margin improved by 410 basis points to 59.4%. AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results
Positive Sentiment: MedTech products continued to drive growth. MedTech sales increased 13.2% to $39.9 million, led by Auryon sales growth of 14.7% and NanoKnife growth of 29.0%. The company also received FDA IDE approval for a NanoKnife feasibility study in benign prostatic hyperplasia. AngioDynamics Reports First-Quarter Sales
Positive Sentiment: Canaccord Genuity reaffirmed its Buy rating and assigned a $20 price target, implying substantial potential upside from recent trading levels. Canaccord Genuity Rating
Neutral Sentiment: Fiscal 2027 guidance was maintained. AngioDynamics continues to forecast revenue of $336 million to $341 million and an adjusted EPS loss of $0.29 to $0.24, broadly consistent with analyst expectations. AngioDynamics Fiscal 2027 Guidance
Negative Sentiment: Leadership uncertainty is weighing on sentiment. Eric Honroth will become president and CEO on November 2, succeeding Jim Clemmer, who is retiring. The transition adds execution risk even as the company attempts to sustain MedTech momentum. AngioDynamics Appoints Eric Honroth CEO
Negative Sentiment: Profitability and liquidity remain concerns. The company remains unprofitable, reported a GAAP net loss of about $7.1 million, and used $15.3 million in operating cash during the quarter. Those factors may have overshadowed the earnings beat and improving margins.

About AngioDynamics

(Get Free Report)

AngioDynamics, Inc is a medical device company that develops, manufactures and markets minimally invasive products for use in vascular disease, vascular access and oncology. Its technologies are designed to help physicians treat blood clots, restore blood flow, manage vascular access and ablate targeted tissue.

The company’s portfolio includes the Auryon platform for atherectomy, which uses laser technology to treat peripheral arterial disease; the AngioVac and AlphaVac systems for removing thrombus and other unwanted material from blood vessels; and BioSentry products used to seal biopsy tracts.